Mutations in <i>ompK36</i> differentially impact <i>in vitro</i> synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing <i>Klebsiella pneumoniae</i>
JAC-antimicrobial resistance